HD-OCT trial: diagnosing basal cell carcinoma (patient recruitment completed)
Sensitivity and specificity of high-definition optical coherence tomography in the evaluation of non-invasive basal cell carcinoma of the skin: a multi-center prospective trial
In preparation: SOPHIA
Randomized phase III trial with Margeheximab plus chemotherapy vs trastuzumab plus chemotherapy in the treatment of patients with HER2/neu positive metastatic mamma carcinoma who have received 2 anti-HER2 therapies in the past.
A neo-adjuvant study with an antibody against PDL1 in triple negative, locally advanced breast cancer who receive a combination with nab-Paclitaxel and Carboplatin.
MM-302 Plus Trastuzumab vs. Chemotherapy of Physician’s Choice Plus Trastuzumab in HER2-Positive Locally Advanced/Metastatic Breast Cancer Patients
A Phase 2, 2-Stage, 2-Cohort Study of Talazoparib (BMN 673), in Locally Advanced and/or Metastatic Breast Cancer Patients With BRCA Mutation
A phase 3, open-label, parallel, 2-Arm, multi-center study of BMN 673 (Parp-Inhibitor) versus physician´s choice in germline BRCA mutation subjects with localy advanced and/or metastatic breast cancer, who have received no more than 2 prior chemotherapy regimens for metastatic disease.
For questions about our clinical trials, please contact our clinical trials coordinator, Simone Schiersner.